The first-ever vaccine for chlamydia treatment is safe and capable of provoking an immune response, according to findings from the phase 1 clinical trial. The vaccine to protect people against the common sexually transmitted infection chlamydia has passed initial safety tests and the results of the clinical trial have been published in The Lancet Infectious Diseases journal. Chlamydia, caused by the bacterium Chlamydia trachomatis, is the most common sexually transmitted bacterial infection worldwide. It presents a major global health burden – with 131 million new cases occurring annually.
Vaccination may be the best way to tackle the epidemic, as national screening programmes and antibiotic treatment have failed to decrease the incidence. But till date, no vaccines against genital chlamydia have been tested in clinical trials. Sonya Abraham, Department of Medicine, Imperial College…
